PURPOSE: To evaluate the usefulness of perfusion parameters derived from dynamic contrast-enhanced MR imaging (DCE-MRI) for assessing the therapeutic response to neoadjuvant chemoradiation therapy (CRT) for locally advanced rectal cancer (LARC). MATERIALS AND METHODS: Fifty patients with LARC (≥T3 or lymph-node metastasis) who underwent CRT and subsequent surgery, were included in this study. All patients underwent pre- and post-CRT DCE-MRI on a 1.5 Tesla unit. By using a postprocessing software, the following perfusion parameters (K(trans) , kep , ve ) were measured for tumor. Those perfusion parameters were compared not only between the T-downstaged group and the nondownstaged group, but also before and after CRT in each group. RESULTS: After CRT, the mean K(trans) (min(-1) ) significantly decreased from 1.24 ± 0.53 to 0.76 ± 0.45 in the T-downstaged group (n = 24) (P = 0.0007), whereas it did not significantly decrease in the nondownstaged group (n = 26) (from 1.02 ± 0.53 to 0.87 ± 0.48, P = 0.24). The percentage difference between pre- and post-CRT K(trans) in the T-downstaged group was significantly higher than that in the nondownstaged group (43%, 16%, respectively, P = 0.0092). However, none of the other parameters showed significant differences. CONCLUSION: A large decrease in the mean K(trans) after CRT was associated with a good therapeutic response to CRT for LARC.
PURPOSE: To evaluate the usefulness of perfusion parameters derived from dynamic contrast-enhanced MR imaging (DCE-MRI) for assessing the therapeutic response to neoadjuvant chemoradiation therapy (CRT) for locally advanced rectal cancer (LARC). MATERIALS AND METHODS: Fifty patients with LARC (≥T3 or lymph-node metastasis) who underwent CRT and subsequent surgery, were included in this study. All patients underwent pre- and post-CRT DCE-MRI on a 1.5 Tesla unit. By using a postprocessing software, the following perfusion parameters (K(trans) , kep , ve ) were measured for tumor. Those perfusion parameters were compared not only between the T-downstaged group and the nondownstaged group, but also before and after CRT in each group. RESULTS: After CRT, the mean K(trans) (min(-1) ) significantly decreased from 1.24 ± 0.53 to 0.76 ± 0.45 in the T-downstaged group (n = 24) (P = 0.0007), whereas it did not significantly decrease in the nondownstaged group (n = 26) (from 1.02 ± 0.53 to 0.87 ± 0.48, P = 0.24). The percentage difference between pre- and post-CRT K(trans) in the T-downstaged group was significantly higher than that in the nondownstaged group (43%, 16%, respectively, P = 0.0092). However, none of the other parameters showed significant differences. CONCLUSION: A large decrease in the mean K(trans) after CRT was associated with a good therapeutic response to CRT for LARC.
Authors: Friedrich H Schmitz-Winnenthal; Nicolas Hohmann; Andreas G Niethammer; Tobias Friedrich; Heinz Lubenau; Marco Springer; Klaus M Breiner; Gerd Mikus; Jürgen Weitz; Alexis Ulrich; Markus W Buechler; Frank Pianka; Ulla Klaiber; Markus Diener; Christine Leowardi; Simon Schimmack; Leila Sisic; Anne-Valerie Keller; Ruhan Koc; Christoph Springfeld; Philipp Knebel; Thomas Schmidt; Yingzi Ge; Mariana Bucur; Slava Stamova; Lilli Podola; Walter E Haefeli; Lars Grenacher; Philipp Beckhove Journal: Oncoimmunology Date: 2015-03-16 Impact factor: 8.110
Authors: Friedrich H Schmitz-Winnenthal; Nicolas Hohmann; Thomas Schmidt; Lilli Podola; Tobias Friedrich; Heinz Lubenau; Marco Springer; Sébastien Wieckowski; Klaus M Breiner; Gerd Mikus; Markus W Büchler; Anne-Valerie Keller; Ruhan Koc; Christoph Springfeld; Phillip Knebel; Mariana Bucur; Lars Grenacher; Walter E Haefeli; Philipp Beckhove Journal: Oncoimmunology Date: 2018-01-16 Impact factor: 8.110